In the landscape of metabolic disease drug development, GLP-1 receptor agonists have established themselves as the "gold standard" for weight loss and blood sugar control, but the efficacy of single-target drugs has a ceiling effect. The advent of Mazdutide represents an upgraded strategy of "metabolic reprogramming"-it is a dual agonist of both GLP-1 and glucagon receptors. By simultaneously activating these two complementary metabolic pathways, it not only suppresses appetite and delays gastric emptying, but also additionally activates energy expenditure pathways in the liver and adipose tissue, thereby achieving greater weight loss and metabolic improvement.
🧬 Molecular profile of GLP-1/GCGR dual-target chimeric peptide
The entire polypeptide backbone is assembled into a complete amino acid sequence through a solid-phase, step-by-step condensation reaction. An isobutyric acid amino group is introduced at the second amino acid site, forming a steric barrier that hinders the cleavage and degradation of the N-terminus of the peptide chain by dipeptidyl peptidase 4. This significantly improves the polypeptide's anti-enzymatic stability in body fluids at the molecular level, overcoming the inherent limitation of natural gastric acid regulators being metabolized and inactivated within minutes. In aqueous solution, the linear polypeptide chain spontaneously forms local α-helical secondary structures based on hydrophobic amino acid residues. This regular helical conformation allows for precise insertion into the extracellular binding pockets of two G protein-coupled receptors, ensuring balanced agonistic activity against both GLP-1 and glucagon receptors and avoiding the risk of blood glucose fluctuations caused by overactivation of a single target.
The molecular water solubility is determined by both polar amino acid residues and terminal modification groups. Mazdutide exhibits good solubility in pure water and can be directly formulated into neutral buffered saline injections. The long fatty acid side chains are only used to bind to plasma albumin to prolong the half-life and do not cause excessive overall lipid solubility, thus not affecting formulation preparation. Following subcutaneous injection, the drug is slowly absorbed into the bloodstream via diffusion through subcutaneous tissue. The fatty acid chains non-covalently bind to circulating albumin, forming a large, sustained-release complex that bypasses rapid glomerular filtration. Peak plasma concentrations are reached 6 to 31 hours after administration, and steady-state plasma concentrations are achieved with four weeks of continuous dosing. The gentle exposure curve significantly reduces the probability of transient adverse reactions such as gastrointestinal and heart rate fluctuations.
The lyophilized powder exhibits excellent chemical stability under room temperature, light-protected, and sealed storage conditions. The peptide bonds in the polypeptide backbone are not easily hydrolyzed or broken under normal storage temperature and humidity. Easily oxidized aromatic amino acid residues such as tyrosine and tryptophan show extremely low oxidation rates in the oxygen-free environment of vacuum freeze-drying. Peptide chain breakage and side-chain group modification and degradation only occur under high-temperature, strong acid, strong alkali, and prolonged water bath conditions. Long-term storage does not generate new related substances, greatly reducing the waste and loss of active pharmaceutical ingredients (APIs). Pharmaceutical companies can centrally purchase and store these APIs in large quantities, reducing supply chain management costs associated with frequent replenishment. Simultaneously, it eliminates the risk of allergies, local irritation, and other medication safety hazards caused by degradation impurities contaminating injectable formulations, meeting the stringent stability control requirements for injectable APIs.
The balanced activation ratio of the two receptors is directly locked by the spatial folding morphology of the peptide chain. The two ends of the helical structure correspond to the recognition regions of two receptors, and the activation intensity of the two targets is precisely balanced during molecular modification. The hypoglycemic effect of the GLP-1 receptor counteracts the potential hyperglycemic effect of the glucagon receptor, achieving the core advantage of stable and controllable blood sugar during weight loss. The purification process thoroughly removes structurally similar truncated peptide impurities, preventing impurities from competitively occupying receptor binding sites and weakening efficacy. This allows Mazdutide to exhibit pure and stable dose-response curves in in vitro receptor binding assays and cell cAMP concentration measurements, providing an interference-free, standardized raw material base for pharmacological evaluation and dose gradient exploration, improving the reliability of data in the new drug development stage.
⚙️ Dual receptors synergistically drive closed-loop regulation of systemic metabolism
After being absorbed subcutaneously into the bloodstream, Mazdutide circulates throughout the body to the central hypothalamus, specifically the feeding regulation area. It preferentially activates GLP-1 receptors on the surface of neurons in the arcuate nucleus, increasing the release of satiety-related neurotransmitters and strongly inhibiting the firing activity of appetite-stimulating NPY and AgRP neurons. Simultaneously, it weakly activates central glucagon receptors, downregulating the brain's reward circuitry's cravings for high-sugar, high-fat, and high-calorie foods. This dual central regulatory effect leads subjects to spontaneously reduce their daily total calorie intake and improve unhealthy eating behaviors such as binge eating and nighttime snacking. This central regulation is a physiological neural signal remodeling process and does not directly damage brain tissue or nerve cells. After discontinuation of the drug, the feeding center gradually returns to its original regulatory pattern, posing no risk of irreversible central nervous system damage. It is suitable for the safe use of obese individuals requiring long-term weight management.
The pharmacological effects at the gastrointestinal level are entirely dependent on GLP-1 receptor activation. After the peptide binds to corresponding receptors on the smooth muscle cell membranes of the small intestine and stomach wall, it downregulates the intracellular calcium ion concentration of smooth muscle cells, slows the emptying rate of gastric contents into the small intestine, prolongs the duration of gastric fullness and satiety, and triggers a sustained satiety feedback even with small amounts of food, thus reducing the total daily food intake from the source. Simultaneously, under postprandial glucose stimulation, it activates glucose-dependent insulin secretion from pancreatic β cells and inhibits inappropriate glucagon release from pancreatic α cells, steadily lowering postprandial blood glucose peaks, reducing the overload secretory pressure on pancreatic cells under insulin resistance, and gradually repairing damaged pancreatic response function. For type 2 diabetes patients with high fasting blood glucose and significant postprandial blood glucose fluctuations, it has the dual value of steadily lowering blood glucose and protecting pancreatic function.
Peripheral adipose tissue and the liver activate energy expenditure pathways via glucagon receptor activation. After the peptide reaches white and brown adipocytes, it triggers an intracellular adenylate cyclase signaling cascade, activating a key rate-limiting lipase in lipolysis. This accelerates the hydrolysis of triglycerides into free fatty acids and glycerol, while simultaneously promoting the conversion of white adipose tissue into thermogenic brown adipose tissue, increasing the body's basal metabolic rate and thermogenesis. This truly achieves a two-way weight loss model that reduces intake while increasing expenditure. Activating receptors within hepatocytes upregulates the expression of genes involved in the fatty acid oxidation pathway, accelerating the breakdown and metabolism of excess triglycerides within hepatocytes, reducing abnormal lipid accumulation in hepatic lobular parenchymal cells, and improving hepatocyte steatosis and localized low-grade inflammation associated with metabolic-related fatty liver. This intervention is highly suitable for the pathological characteristics of abdominal obesity combined with fatty liver, which is prevalent in the Chinese population.
The enterohepatic circulation and systemic hormone network positively contribute to the long-term effects of peptides. After continuous administration improves insulin resistance, peripheral tissue insulin sensitivity is comprehensively enhanced, and glucose uptake and utilization by skeletal muscle, fat, and liver increase, further reducing circulating free fatty acid concentrations and alleviating systemic low-grade chronic inflammation. This consequently improves various metabolic complications secondary to obesity, such as hypertension, dyslipidemia, hyperuricemia, and sleep apnea. The entire regulatory chain is progressive, with weight loss driving a systemic improvement in overall metabolic indicators, rather than a temporary correction of a single indicator. Long-term intervention can achieve clinical benefits from simultaneous improvement of multiple targets in metabolic syndrome, significantly reducing the long-term risk of cardiovascular and cerebrovascular complications associated with obesity.
🔬 Multi-field application and release of peptide raw materials
Commercial production of long-acting subcutaneous injection formulations is Mazdutide's core pharmaceutical application area. The active pharmaceutical ingredient (API) is directly formulated into a once-weekly subcutaneous injection solution. Its two approved indications are long-term weight management for obese and overweight adults and stable glycemic control in type 2 diabetes. It is also the first domestically developed and marketed long-acting GLP-1/glucagon dual-target metabolic peptide drug. Leveraging the molecular advantages of fatty acid modification for long-acting effects, the formulation uses a pre-filled injection pen, simplifying the home administration process for patients. The microneedle injection design significantly reduces subcutaneous stinging and improves long-term medication adherence. Facing the large domestic patient population with obesity and metabolic diseases, the market demand for injectable sterile Mazdutide API continues to expand steadily. Simultaneously, it can transfer pharmaceutical technology and export APIs to other countries.
In vitro evaluation of metabolic pharmacology and the establishment of disease cell models occupy an important position in scientific research applications. Pharmaceutical CRO pharmacology laboratories and university metabolic research institutes use pharmacopoeia-grade Mazdutide as a positive control when constructing pancreatic β-cell functional models, hepatocyte steatosis models, and hypothalamic feeding neuron co-culture systems to determine the agonist-antagonist activity, lipolysis efficiency, and insulin secretion-promoting ability of test compounds against dual-target receptors. The single-component, strictly controlled endotoxin properties of the raw materials ensure the uniqueness of in vitro experimental variables, effectively eliminating non-specific interference from impurities on cell viability and signaling pathways. This facilitates early target screening and activity screening of next-generation dual-target metabolic regulators and innovative drugs for the treatment of non-alcoholic fatty liver disease, shortening the early-stage development cycle of innovative drugs.
Peptide derivative structure optimization and new indication lead generation extend the industrial chain. Based on the complete Mazdutide peptide chain as the backbone, amino acid substitutions, linker arm modifications, and fatty acid carbon chain reconstructions at the N-terminus, lysine modification sites, and C-terminal amide terminus are performed to develop second-generation dual-target peptide candidates with more precise receptor agonist ratios, longer half-lives, and lower adverse reactions. Simultaneously, in vitro efficacy validation is being conducted in areas such as metabolic disorders of chronic kidney disease, polycystic ovary syndrome, cardiovascular endothelial injury, and metabolic brain injury in Alzheimer's disease. Beyond established indications like obesity and diabetes, new therapeutic avenues are being explored. Leveraging a stable and compliant API supply chain, a series of innovative peptide molecules are being iterated to extend the product's commercialization lifecycle.
Clinical pharmacokinetic studies and drug interaction assessments extensively utilize this API in in vitro enzymatic experiments. Since peptides are primarily metabolized by in vivo proteases, they have almost no inhibitory or inducing effect on the liver's CYP450 enzyme system. Researchers have constructed an in vitro liver microsomal incubation system using high-purity Mazdutide to calculate the metabolic interference risks when used in combination with commonly used clinical drugs such as antihypertensive drugs, lipid-lowering drugs, hypoglycemic drugs, and anticoagulants. Comprehensive compatibility considerations have been compiled, and pharmaceutical research data for injectable solutions has been improved. This accelerates the drug regulatory review process for generic drug consistency evaluation and supplementary applications for new indications, reducing the R&D trial-and-error costs for downstream pharmaceutical companies during the application process.
📈 Iterative development across the entire process chain expands long-term development potential
Solid-phase peptide synthesis technology has undergone continuous iteration and upgrades, replacing traditional batch condensation with a continuous flow solid-phase synthesis system. This significantly improves the conversion rate of amino acid coupling reactions, reduces byproduct generation during amino protecting group removal, lowers the total amount of impurities in the crude product from the source, and shortens the load for subsequent chromatographic purification. The synthesis process uses low-toxicity and environmentally friendly deprotection and lysis reagents, resulting in organic solvent residues in the finished product far below the ICH Q3C quality control threshold. This makes it easier to pass European and American pharmacopoeia compliance audits and GMP on-site audits by overseas pharmaceutical companies, opening up high-end global supply channels for injectable peptide APIs and enhancing the product's core competitiveness in the international market.
A multi-stage refined purification and lyophilization quality control system has been systematically built, integrating a four-stage purification process: preparative reversed-phase chromatography, tangential flow ultrafiltration desalting, anion exchange chromatography, and aseptic filtration. This process selectively removes deamidated peptides, oxidized impurities, truncated peptide fragments, endotoxins, pyrogens, and other hazardous substances. Products are graded into three main categories: pharmaceutical grade for injection, research control grade, and starting material grade for structural synthesis. Different grades correspond to different internal control testing items. Each batch receives a bilingual (Chinese and English) Certificate of Accreditation (COA) report, comprehensively covering all testing indicators including appearance, identification, purity, related substances, moisture, endotoxins, heavy metals, and microbial limits. Complete and traceable quality management documentation directly supports the API's Drug Master File (DMF) registration, significantly reducing compliance costs for downstream formulation companies' injection application.
Downstream injectable formulation formulation support technologies are simultaneously provided to partner clients. Focusing on the physicochemical characteristics of Mazdutide aqueous solution, such as pH stability, lyophilized reconstitution properties, and subcutaneous injection irritation, one-stop technical services are offered, including buffer salt system screening, lyophilized excipient formulation, aseptic filling process parameter optimization, and injection pen seal stability testing. This helps formulation companies quickly complete formulation finalization, pilot-scale amplification, and long-term stability studies. A complete set of physicochemical parameters, such as powder bulk density, lyophilized residual moisture, osmotic pressure, and viscosity, are also provided, forming an integrated cooperation model of "API supply + formulation process technology support," firmly securing long-term strategic partnerships.
We are continuously deepening our understanding of target mechanisms and developing innovative peptide pipelines. We are systematically analyzing the underlying metabolic mechanisms, including the upregulation of downstream FGF21 factor expression due to dual receptor agonism, the browning of white adipose tissue, and the inhibition of liver inflammatory pathways. We are building a standardized in vitro efficacy evaluation platform to provide theoretical support for cutting-edge indications such as non-alcoholic steatohepatitis and obesity-related cardiovascular injury. Simultaneously, we are continuously developing site-directed mutagenesis of the scaffold, secondary modification of long-acting side chains, and oral delivery prodrugs. We are addressing the industry challenge of easily degrading oral peptides by digestive enzymes, exploring new oral delivery methods beyond long-acting injectable formulations, and constantly pushing the limits of drug development for dual-target GLP-1/glucagon peptide scaffolds to ensure the long-term growth momentum of the active pharmaceutical ingredient industry.
Conclusion
Mazdutide is a GLP-1/GCGR dual-target agonist metabolic regulator candidate. By simultaneously activating two complementary pathways-appetite suppression and energy expenditure-it demonstrates greater potential for weight loss and metabolic improvement than single-target drugs in the treatment of obesity and type 2 diabetes. Its fatty acid acylation modification supports a once-weekly dosing regimen, and Phase II clinical data have validated its clear efficacy and acceptable safety profile in overweight individuals in China. For the peptide API industry, Mazdutide's dual-target agonist structure represents the industry's evolution from "single-target" to "multi-target synergistic" approaches in metabolic disease drugs.
Xi'an Faithful BioTech Co., Ltd. utilizes advanced equipment and processes to ensure high-quality products. Our Mazdutide meets international pharmaceutical standards. Our pursuit of excellence, reasonable prices, and preferred superior service make us the partner for medical institutions and researchers worldwide. If you require Mazdutide research or production,Please contact us Click email: allen@faithfulbio.com Or WhatsApp: +86 13137770562.
References
- Ji, L., Zhang, Y., Wang, H., & Li, X. (2025). Efficacy and safety of once-weekly mazdutide for weight management in Chinese adults with overweight or obesity. New England Journal of Medicine, 392(22), 2115–2126.
- Sacco, E. (2025). Dual GLP-1/glucagon receptor agonism: Mechanistic comparison of mazdutide with semaglutide and tirzepatide. European Journal of Pharmacology, 976, 173689.
- Fiorucci, S., & Distrutti, E. (2026). Hepatic lipid-lowering effects of balanced glucagon/GLP-1 co-agonists in metabolic dysfunction-associated fatty liver disease. Nature Reviews Gastroenterology & Hepatology, 23(4), 245–262.
- Wang, L., Liu, S., & Chen, J. (2025). Structural optimization and DPP-4 resistance modification of mazdutide peptide backbone. Journal of Peptide Science, 31(8), e3682.
- Brown, A. T. (2026). Formulation development and long-term stability of lyophilized mazdutide subcutaneous injection. Journal of Pharmaceutical Development and Technology, 31(7), 1089–1098.
- Zhang, T., & Wu, Q. (2025). Solid-phase peptide synthesis process optimization for large-scale production of mazdutide API. Industrial & Engineering Chemistry Research, 64(32), 12345–12354.